GoAI
Get started
Jilin Province Huinan Changlong Bio-pharmacy Company Limited logo

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

8049.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$2.33

+HK$0.005 · +0.22%

Aug 21, 1:02 PM HKT

8049.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Hong Zhang
Listed since
May 24, 2001
Employees
1,107

Market position

52-week range

Current HK$2.33

Open
HK$2.33
Previous close
HK$2.325
Volume
74K
0.89× average
Average volume
82.78K
Average daily volume
Market cap
1.31B HKD
Beta
0.29
Market reference 1
50-day average
HK$2.3694
-1.66% below average
200-day average
HK$2.2681
+2.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
4.13×
P/B (TTM)
0.62×
P/S (TTM)
1.01×
Dividend yield
12.33%

Profitability & efficiency

Gross margin
84.30%
Operating margin
29.43%
Net margin
24.16%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends91%64%38%11%Gross margin, FY2021: 82.22%Gross margin, FY2022: 77.00%Gross margin, FY2023: 69.40%Gross margin, FY2024: 77.77%Gross margin, FY2025: 84.01%Operating margin, FY2021: 25.18%Operating margin, FY2022: 23.51%Operating margin, FY2023: 23.63%Operating margin, FY2024: 23.74%Operating margin, FY2025: 23.80%Net margin, FY2021: 20.31%Net margin, FY2022: 23.00%Net margin, FY2023: 17.61%Net margin, FY2024: 20.91%Net margin, FY2025: 22.05%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 82.22%. Gross margin FY2022 77.00%. Gross margin FY2023 69.40%. Gross margin FY2024 77.77%. Gross margin FY2025 84.01%. Operating margin FY2021 25.18%. Operating margin FY2022 23.51%. Operating margin FY2023 23.63%. Operating margin FY2024 23.74%. Operating margin FY2025 23.80%. Net margin FY2021 20.31%. Net margin FY2022 23.00%. Net margin FY2023 17.61%. Net margin FY2024 20.91%. Net margin FY2025 22.05%.

Income trends

Revenue

901.87M HKD+2.35%

Operating income

214.6M HKD+2.59%

Net income

198.88M HKD+7.94%
Income trends across reported periods977.73M HKD674.29M HKD370.86M HKD67.42M HKDRevenue, FY2021: 705.46M HKDRevenue, FY2022: 841.59M HKDRevenue, FY2023: 841.55M HKDRevenue, FY2024: 881.16M HKDRevenue, FY2025: 901.87M HKDOperating income, FY2021: 177.62M HKDOperating income, FY2022: 197.82M HKDOperating income, FY2023: 198.83M HKDOperating income, FY2024: 209.19M HKDOperating income, FY2025: 214.6M HKDNet income, FY2021: 143.28M HKDNet income, FY2022: 193.57M HKDNet income, FY2023: 148.21M HKDNet income, FY2024: 184.25M HKDNet income, FY2025: 198.88M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 705.46M HKD. Revenue FY2022 841.59M HKD. Revenue FY2023 841.55M HKD. Revenue FY2024 881.16M HKD. Revenue FY2025 901.87M HKD. Operating income FY2021 177.62M HKD. Operating income FY2022 197.82M HKD. Operating income FY2023 198.83M HKD. Operating income FY2024 209.19M HKD. Operating income FY2025 214.6M HKD. Net income FY2021 143.28M HKD. Net income FY2022 193.57M HKD. Net income FY2023 148.21M HKD. Net income FY2024 184.25M HKD. Net income FY2025 198.88M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue901.87M HKD881.16M HKD841.55M HKD841.59M HKD705.46M HKD
Cost of goods sold144.2M HKD195.91M HKD257.5M HKD193.55M HKD125.45M HKD
Gross profit757.67M HKD685.25M HKD584.05M HKD648.04M HKD580.01M HKD
Research and development——13.1M HKD19.06M HKD20.58M HKD
Selling, general, and administrative561.36M HKD522.19M HKD448.95M HKD509.95M HKD454M HKD
Operating expenses543.07M HKD476.06M HKD385.22M HKD450.21M HKD401.65M HKD
Interest income48.68M HKD18.76M HKD33.12M HKD35.31M HKD33.59M HKD
Interest expense1.39M HKD2.03M HKD515K HKD477K HKD344K HKD
Depreciation and amortization28.34M HKD27.14M HKD27.56M HKD33.6M HKD28.88M HKD
Operating income214.6M HKD209.19M HKD198.83M HKD197.82M HKD177.62M HKD
Net income198.88M HKD184.25M HKD148.21M HKD193.57M HKD143.28M HKD

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.2729

2025 complete year+279.9% since 2021

2026 partial: HK$0.2873

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 22, 2026

HK$0.2873

Special

Record Jun 24, 2026 · Payment Jul 10, 2026

Dividend

Ex-dividend Jun 24, 2025

HK$0.2729

Special

Record Jun 26, 2025 · Payment Jul 18, 2025

Dividend

Ex-dividend Jun 18, 2024

HK$0.0686

Special

Record Jun 19, 2024 · Payment Jul 16, 2024

Dividend

Ex-dividend Jun 8, 2023

HK$0.5533

Special

Record Jun 9, 2023 · Payment Jun 30, 2023

Dividend

Ex-dividend Jul 26, 2022

HK$0.0732

Special

Record Jul 27, 2022 · Payment Aug 31, 2022

Dividend

Ex-dividend Oct 15, 2021

HK$0.0316

Special

Record Oct 18, 2021 · Payment Nov 18, 2021

8049.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 8049.HK

research.disclaimer